Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2020

01-04-2020 | Dysthymic Disorder | Review

Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review

Authors: Harsh Patel, Victor Arruarana, Lucille Yao, Xiaojiang Cui, Edward Ray

Published in: Endocrine | Issue 1/2020

Login to get access

Abstract

Purpose

Hormone replacement therapy (HRT) has become a mainstay medical treatment option for management of gender dysphoria in transgender patients of both biologic sexes. Very little is known about the long-term effects of steroid hormone modulation on breast tissue in this population. Most of the data available on the effects of HRT on breast and reproductive tissues come from studies of postmenopausal cisgender women. Therapeutic regimens are often provider-dependent, and there, are no uniform guidelines in place for cancer surveillance in transgender patients. In this review, we present what forms of hormone therapy and hormone modulation are available to transgender patients, what is known about their effects on male and female breast tissue, and what other endogenous and exogenous factors contribute to the macroscopic and cellular changes observed.

Methods

A search for the existing literature focusing on therapeutic regimens and the effects of HRT on breast tissue provided the most current information available for this review. Recent evidence-based reports (since the year 2000) and reviews were given priority over anecdotal evidence and expert opinions when conflicting information was encountered. Older resources were considered when primary sources were needed. Given the paucity of available articles on this subject, all resources were given careful consideration.

Results

Information about the risks associated with HRT in the current literature and in this setting is limited and often conflicting, due to a scarcity of long-term studies tracking breast pathology among transgender men and women.

Conclusions

We conclude that the long-term effects of off-label pharmaceutical use for modulation of hormone levels and sexual characteristics in transgender patients have not been well studied. The tendency of steroid hormones to promote the growth of certain cancers also raises questions about the safety of differing doses and drug combinations. Further clinical and laboratory study is needed to better establish safety and dosing guidelines in transgender patients.
Literature
1.
G. Heylens, C. Verroken, S. De Cock, G. T’Sjoen, G. De Cuypere, Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J. Sex. Med. 11(1), 119–126 (2014)PubMed
2.
L. Hashemi, J. Weinreb, A.K. Weimer, R.L. Weiss, Transgender care in the primary care setting: a review of guidelines and literature. Fed. Pract. 35(7), 30–37 (2018)PubMedPubMedCentral
3.
E.B. Sonnenblick, A.D. Shah, Z. Goldstein, T. Reisman, Breast imaging of transgender individuals: a review. Curr. Radiol. Rep. 6(1), 1 (2018)PubMedPubMedCentral
4.
H.B. Nguyen, A.M. Chavez, E. Lipner, L. Hantsoo, S.L. Kornfield, R.D. Davies, C.N. Epperson, Gender-affirming hormone use in transgender individuals: impact on behavioral health and cognition. Curr. Psychiatry Rep. 20(12), 110 (2018)PubMedPubMedCentral
5.
W.C. Hembree, P.T. Cohen-Kettenis, L. Gooren, S.E. Hannema, W.J. Meyer, M.H. Murad, S.M. Rosenthal, J.D. Safer, V. Tangpricha, G.G. T’Sjoen, Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 102(11), 3869–3903 (2017)PubMed
6.
I. Gardner, J.D. Safer, Progress on the road to better medical care for transgender patients. Current Opinion in Endocrinology, Diabetes and Obesity 20(6), 553–558 (2013)
7.
8.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Rockville, Md.: U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs, 2018. Internet resource
9.
J.J. Shoskes, M.K. Wilson, M.L. Spinner, Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 5(6), 834–843 (2016)PubMedPubMedCentral
10.
P.S. Cooke, M.K. Nanjappa, C. Ko, G.S. Prins, R.A. Hess, Estrogens in male physiology. Physiol. Rev. 97(3), 995–1043 (2017)PubMedPubMedCentral
11.
D.A. Gibson, P.T. Saunders, Estrogen dependent signaling in reproductive tissues—a role for estrogen receptors and estrogen related receptors. Mol. Cell. Endocrinol. 348(2), 361–372 (2012)PubMed
12.
T. Deli, M. Orosz, A. Jakab, Hormone replacement therapy in cancer survivors—review of the literature. Pathol. Oncol. Res. (2019)
13.
J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, J. Ockene; Writing Group for the Women’s Health Initiative I, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3), 321–333 (2002)PubMed
14.
I. Vaz-Luis, A.H. Partridge, Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat. Rev. Clin. Oncol. 15(4), 249–261 (2018)PubMed
15.
J. Simin, R. Tamimi, J. Lagergren, H.O. Adami, N. Brusselaers, Menopausal hormone therapy and cancer risk: an overestimated risk? Eur. J. Cancer 84, 60–68 (2017)PubMed
16.
Collaborative Group on Hormonal Factors in Breast Cancer T, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 350(9084), 1047–1059 (1997)
17.
V. Tangpricha, M. den Heijer, Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 5(4), 291–300 (2017)PubMed
18.
M.S. Irwig, Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 5(4), 301–311 (2017)PubMed
19.
A. Nimrod, K.J. Ryan, Aromatization of androgens by human abdominal and breast fat tissue. J. Clin. Endocrinol. Metab. 40(3), 367–372 (1975)PubMed
20.
K.J. Chan, D. Jolly, J.J. Liang, J.D. Weinand, J.D. Safer, Estrogen levels do not rise with testosterone treatment for transgender men. Endocr. Pract. 24(4), 329–333 (2018)PubMed
21.
M. Grynberg, R. Fanchin, G. Dubost, J.C. Colau, C. Bremont-Weil, R. Frydman, J.M. Ayoubi, Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod. Biomed. Online 20(4), 553–558 (2010)PubMed
22.
M.H. Slagter, L.J. Gooren, A. Scorilas, C.D. Petraki, E.P. Diamandis, Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J. Histochem. Cytochem. 54(8), 905–910 (2006)PubMed
23.
H. Asscheman, E.J. Giltay, J.A. Megens, W.P. de Ronde, M.A. van Trotsenburg, L.J. Gooren, A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol. 164(4), 635–642 (2011)PubMed
24.
R.L. Hartley, J.P. Stone, C. Temple-Oberle, Breast cancer in transgender patients: a systematic review. Part 1: male to female. Eur. J. Surg. Oncol. 44(10), 1455–1462 (2018)PubMed
25.
J.P. Stone, R.L. Hartley, C. Temple-Oberle, Breast cancer in transgender patients: a systematic review. Part 2: female to male. Eur. J. Surg. Oncol. 44(10), 1463–1468 (2018)PubMed
26.
M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505–518 (2004)PubMed
27.
C. Carter-Su, J. Schwartz, L.S. Argetsinger, Growth hormone signaling pathways. Growth Horm. IGF Res. 28, 11–15 (2016)PubMed
28.
A.J. Stewart, M.D. Johnson, F.E. May, B.R. Westley, Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265(34), 21172–21178 (1990)PubMed
29.
N. Nota, M. Klaver, C. Wiepjes, M. Dekker, A. Heijboer, M. Heijer Den, Increase in Insulin-like Growth Factor Levels During Cross-sex Hormone Treatment in Transgender Persons. 18th European Congress of Endocrinology (Munich, 2016)
30.
D.L. Kleinberg, T.L. Wood, P.A. Furth, A.V. Lee, Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr. Rev. 30(1), 51–74 (2009)PubMedPubMedCentral
31.
B.W. Hartmann, T. Laml, S. Kirchengast, A.E. Albrecht, J.C. Huber, Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I. Gynecol. Endocrinol. 12(2), 123–127 (1998)PubMed
32.
H.S. Narula, H.E. Carlson, Gynaecomastia—pathophysiology, diagnosis and treatment. Nat. Rev. Endocrinol. 10(11), 684–698 (2014)PubMed
33.
W. Ruan, M.E. Monaco, D.L. Kleinberg, Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology 146(3), 1170–1178 (2005)PubMed
34.
D.L. Kleinberg, Role of IGF-I in normal mammary development. Breast Cancer Res. Treat. 47(3), 201–208 (1998)PubMed
35.
T. Nickerson, F. Chang, D. Lorimer, S.P. Smeekens, C.L. Sawyers, M. Pollak, In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61(16), 6276–6280 (2001)PubMed
36.
G.O. Hellawell, G.D. Turner, D.R. Davies, R. Poulsom, S.F. Brewster, V.M. Macaulay, Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62(10), 2942–2950 (2002)PubMed
37.
M. Gebre-Medhin, L.G. Kindblom, H. Wennbo, J. Tornell, J.M. Meis-Kindblom, Growth hormone receptor is expressed in human breast cancer. Am. J. Pathol. 158(4), 1217–1222 (2001)PubMedPubMedCentral
38.
J.E. Hall, Guyton and Hall textbook of medical physiology. 13th edn. (Elsevier, Philadelphia, PA)
39.
A. Pezet, H. Buteau, P.A. Kelly, M. Edery, The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor. Mol Cell Endocrinol. 129(2), 199–208 (1997)PubMed
40.
S. Gerlo, J.R. Davis, D.L. Mager, R. Kooijman, Prolactin in man: a tale of two promoters. Bioessays 28(10), 1051–1055 (2006)PubMedPubMedCentral
41.
M. Zinger, M. McFarland, N. Ben-Jonathan, Prolactin expression and secretion by human breast glandular and adipose tissue explants. J. Clin. Endocrinol. Metab. 88(2), 689–696 (2003)PubMed
42.
K. Foitzik, E.A. Langan, R. Paus, Prolactin and the skin: a dermatological perspective on an ancient pleiotropic peptide hormone. J. Investig. Dermatol. 129(5), 1071–1087 (2009)PubMed
43.
M.T. Nevalainen, E.M. Valve, P.M. Ingleton, M. Nurmi, P.M. Martikainen, P.L. Harkonen, Prolactin and prolactin receptors are expressed and functioning in human prostate. J. Clin. Investig. 99(4), 618–627 (1997)PubMed
44.
I.G. Camarillo, G. Thordarson, J.G. Moffat, K.M. Van Horn, N. Binart, P.A. Kelly, F. Talamantes, Prolactin receptor expression in the epithelia and stroma of the rat mammary gland. J. Endocrinol. 171(1), 85–95 (2001)PubMed
45.
T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. N. Am. 37(1), 67–99 (2008)
46.
J.N. Ihle, STATs: signal transducers and activators of transcription. Cell 84(3), 331–334 (1996)PubMed
47.
A.R. Glass, Gynecomastia. Endocrinol. Metab. Clin. N. Am. 23(4), 825–837 (1994)
48.
N. Cuhaci, S.B. Polat, B. Evranos, R. Ersoy, B. Cakir, Gynecomastia: clinical evaluation and management. Indian J. Endocrinol. Metab. 18(2), 150–158 (2014)PubMedPubMedCentral
49.
B.M. Stringer, J. Rowson, E.D. Williams, Effect of raised serum prolactin on breast development. J. Anat. 162, 249–261 (1989)PubMedPubMedCentral
50.
S. Mahfouda, J.K. Moore, A. Siafarikas, F.D. Zepf, A. Lin, Puberty suppression in transgender children and adolescents. Lancet Diabetes Endocrinol. 5(10), 816–826 (2017)PubMed
51.
G. Di Lorenzo, R. Autorino, S. Perdona, S. De Placido, Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol. 6(12), 972–979 (2005)PubMed
52.
B.P.C. Kreukels, T.D. Steensma, A.L.C.D. Vries, Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge (Springer, Heidelberg)
53.
A. Mosenkis, R.R. Townsend, Gynecomastia and antihypertensive therapy. J. Clin. Hypertens. 6(8), 469–470 (2004)
54.
M. Gil, B. Oliva, J. Timoner, M.A. Macia, V. Bryant, F.J. de Abajo, Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br. J. Clin. Pharmacol. 72(6), 965–968 (2011)PubMedPubMedCentral
55.
D. Chew, J. Anderson, K. Williams, T. May, K. Pang, Hormonal treatment in young people with gender dysphoria: a systematic review. Pediatrics. 141(4), pii: e20173742 (2018)
56.
L.A. Tanner, L.A. Bosco, Gynecomastia associated with calcium channel blocker therapy. Arch. Intern. Med. 148(2), 379–380 (1988)PubMed
57.
K.B. Hammons, R.F. Edwards, W.Y. Rice, Golf-inhibiting gynecomastia associated with atorvastatin therapy. Pharmacotherapy 26(8), 1165–1168 (2006)PubMed
58.
Y. Nakamura, K. Yoshimoto, S. Saima, Gynaecomastia induced by angiotensin converting enzyme inhibitor. BMJ 300(6723), 541 (1990)PubMedPubMedCentral
59.
E.B. Lewinn, Gynecomastia during digitalis therapy; report of eight additional cases with liver-function studies. N. Engl. J. Med. 248(8), 316–320 (1953)PubMed
60.
L. Green, D.K. Wysowski, J.L. Fourcroy, Gynecomastia and breast cancer during finasteride therapy. N. Engl. J. Med. 335(11), 823 (1996)PubMed
61.
K.W. Hagberg, H.A. Divan, S.C. Fang, J.C. Nickel, S.S. Jick, Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin. Epidemiol. 9, 83–91 (2017)PubMedPubMedCentral
62.
M.J. Sikora, J.M. Rae, M.D. Johnson, Z. Desta, Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. HIV Med. 11(9), 603–607 (2010)PubMedPubMedCentral
63.
M. Chiba, L. Jin, W. Neway, J.P. Vacca, J.R. Tata, K. Chapman, J.H. Lin, P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. Drug Metab. Dispos. 29(1), 1–3 (2001)PubMed
64.
D.S. Grosso, T.W. Boyden, R.W. Pamenter, D.G. Johnson, D.A. Stevens, J.N. Galgiani, Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob. Agents Chemother. 23(2), 207–212 (1983)PubMedPubMedCentral
65.
T.C. Fagan, D.G. Johnson, D.S. Grosso, Metronidazole-induced gynecomastia. JAMA 254(22), 3217 (1985)PubMed
66.
R. Dixit, S. Sharma, C.L. Nawal, Gynaecomastia during antituberculosis chemotherapy with isoniazid. J. Assoc. Physicians India 56, 390–391 (2008)PubMed
67.
N. Morrone, N. Morrone Jr, A.G. Braz, J.A. Maia, Gynecomastia: a rare adverse effect of isoniazid. J. Bras. Pneumol. 34(11), 978–981 (2008)PubMed
68.
L.A. Garcia Rodriguez, H. Jick, Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 308(6927), 503–506 (1994)PubMedPubMedCentral
69.
70.
T. Poteat, A.L. Wirtz, A. Radix, A. Borquez, A. Silva-Santisteban, M.B. Deutsch, S.I. Khan, S. Winter, D. Operario, HIV risk and preventive interventions in transgender women sex workers. Lancet 385(9964), 274–286 (2015)PubMed
71.
S.D. Baral, T. Poteat, S. Stromdahl, A.L. Wirtz, T.E. Guadamuz, C. Beyrer, Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect. Dis. 13(3), 214–222 (2013)PubMed
72.
K.H. Mayer, B. Grinsztejn, W.M. El-Sadr, Transgender people and HIV prevention: what we know and what we need to know, a call to action. J. Acquir. Immune Defic. Syndr. 72(Suppl 3), S207–S209 (2016)PubMedPubMedCentral
73.
J.M. White Hughto, S.L. Reisner, J.E. Pachankis, Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc. Sci. Med. 147, 222–231 (2015)PubMedPubMedCentral
74.
S.J. Hwahng, L. Nuttbrock, Sex workers, fem queens, and cross-dressers: differential marginalizations and HIV vulnerabilities among three ethnocultural male-to-female transgender communities in New York City. Sex. Res. Soc. Policy 4(4), 36–59 (2007)
75.
S. Addis, M. Davies, G. Greene, S. Macbride-Stewart, M. Shepherd, The health, social care and housing needs of lesbian, gay, bisexual and transgender older people: a review of the literature. Health Soc. Care Commun. 17(6), 647–658 (2009)
76.
J. Bradford, S.L. Reisner, J.A. Honnold, J. Xavier, Experiences of transgender-related discrimination and implications for health: results from the Virginia Transgender Health Initiative Study. Am. J. Public Health 103(10), 1820–1829 (2013)PubMedPubMedCentral
77.
J.B. Fletcher, K.A. Kisler, C.J. Reback, Housing status and HIV risk behaviors among transgender women in Los Angeles. Arch. Sex. Behav. 43(8), 1651–1661 (2014)PubMedPubMedCentral
78.
S.P. Kurtz, H.L. Surratt, M.C. Kiley, J.A. Inciardi, Barriers to health and social services for street-based sex workers. J. Health Care Poor Underserv. 16(2), 345–361 (2005)
79.
K.L. Nadal, K.C. Davidoff, W. Fujii-Doe, Transgender women and the sex work industry: roots in systemic, institutional, and interpersonal discrimination. J. Trauma Dissociation 15(2), 169–183 (2014)PubMed
80.
J.D. Safer, E. Coleman, J. Feldman, R. Garofalo, W. Hembree, A. Radix, J. Sevelius, Barriers to healthcare for transgender individuals. Curr. Opin. Endocrinol. Diabetes Obes. 23(2), 168–171 (2016)PubMedPubMedCentral
81.
N.F. Sanchez, J.P. Sanchez, A. Danoff, Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am. J. Public Health 99(4), 713–719 (2009)PubMedPubMedCentral
82.
J.D. Safer, E.N. Pearce, A simple curriculum content change increased medical student comfort with transgender medicine. Endocr. Pract. 19(4), 633–637 (2013)PubMed
83.
D.D. Thomas, J.D. Safer, A simple intervention raised resident-physician willingness to assist transgender patients seeking hormone therapy. Endocr. Pract. 21(10), 1134–1142 (2015)PubMed
84.
A. Metastasio, A. Negri, G. Martinotti, O. Corazza, Transitioning bodies. The case of self-prescribing sexual hormones in gender affirmation in individuals attending psychiatric services. Brain Sci. 8(5), pii: E88 (2018)
85.
C.J.M. de Blok, C.M. Wiepjes, N.M. Nota, K. van Engelen, M.A. Adank, K.M.A. Dreijerink, E. Barbe, I. Konings, M. den Heijer, Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 365, l1652 (2019)PubMedPubMedCentral
86.
Y. Kojima, N. Takahashi, N. Haga, M. Nomiya, T. Yanagida, K. Ishibashi, K. Aikawa, D.I. Lee, Urinary incontinence after robot-assisted radical prostatectomy: pathophysiology and intraoperative techniques to improve surgical outcome. Int. J. Urol. 20(11), 1052–1063 (2013)PubMed
Metadata
Title
Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review
Authors
Harsh Patel
Victor Arruarana
Lucille Yao
Xiaojiang Cui
Edward Ray
Publication date
01-04-2020
Publisher
Springer US
Published in
Endocrine / Issue 1/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02197-5

Other articles of this Issue 1/2020

Endocrine 1/2020 Go to the issue

Endocrine Genetics/Epigenetics

Epigenetic mechanism in search for the pathomechanism of diabetic neuropathy development in diabetes mellitus type 1 (T1DM)

Review

Acromegaly in the elderly patients

Meta-Analysis

Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis

Original Article

Impact of acute-phase insulin secretion on glycemic variability in insulin-treated patients with type 2 diabetes

Original Article

Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst—a single-center experience

Original Article

Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits